KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Net Income (2016 - 2025)

Historic Net Income for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$9.9 million.

  • Neogenomics' Net Income rose 3551.94% to -$9.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$108.0 million, marking a year-over-year decrease of 3721.64%. This contributed to the annual value of -$108.0 million for FY2025, which is 3721.64% down from last year.
  • Neogenomics' Net Income amounted to -$9.9 million in Q4 2025, which was up 3551.94% from -$27.1 million recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Net Income registered a high of $75.9 million during Q2 2021, and its lowest value of -$49.4 million during Q1 2022.
  • Moreover, its 5-year median value for Net Income was -$23.5 million (2022), whereas its average is -$21.4 million.
  • Over the last 5 years, Neogenomics' Net Income had its largest YoY gain of 121185.52% in 2021, and its largest YoY loss of 89577.63% in 2021.
  • Neogenomics' Net Income (Quarter) stood at -$41.8 million in 2021, then surged by 45.67% to -$22.7 million in 2022, then skyrocketed by 36.85% to -$14.3 million in 2023, then fell by 6.97% to -$15.3 million in 2024, then skyrocketed by 35.52% to -$9.9 million in 2025.
  • Its Net Income stands at -$9.9 million for Q4 2025, versus -$27.1 million for Q3 2025 and -$45.1 million for Q2 2025.